Immuneering Corp (IMRX) Stock Analysis
Verdict: WATCH (do not buy)
Ample $128.6M cash runway and insider buying buffer IMM-1-104 clinical risk — trial readouts remain the decisive binary catalyst.
Investment score: 53/100
Analysis as of
Is Immuneering Corp stock worth reviewing? AI model thesis
The AI model views Immuneering Corp as a speculative hold. While pre-revenue burn poses binary clinical risk, $128.65M in cash ($2.92/share) provides ~34 months of runway, backed by insider buying from C-suite executives.
7-factor investment score
- Valuation: 40/100 (weight 20%)
- Financial Health: 55/100 (weight 15%)
- Technical Momentum: 35/100 (weight 15%)
- Earnings Quality: 65/100 (weight 15%)
- Insider Sentiment: 75/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 45/100 (weight 15%)
Immuneering Corp opportunities and risks
What speaks for IMRX
- Robust cash reserve of $128.65M provides a 34-month operational runway
What speaks against IMRX
- Binary clinical trial failure or data disappointment in lead oncology programs
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| IMRX | n/a | 0.0x | n/a | 0.0% | 0.0% | -35.3% |
| CYDY | n/a | 0.0x | n/a | 0.0% | 0.0% | -6.3% |
| UPB | n/a | 92.2x | n/a | 98.4% | -4955.7% | -46.8% |
| PALI | n/a | 602.3x | n/a | 100.0% | -6388.2% | -6.0% |
| CYPH | 5.2x | 0.0x | n/a | 0.0% | 0.0% | -8.3% |
| Peer median | n/a | 46.1x | n/a | 49.2% | -2477.8% | -7.3% |
Frequently asked questions about Immuneering Corp (IMRX)
Is IMRX stock a good investment?
The cached TradeMates AI model rates Immuneering Corp as WATCH (do not buy) with an investment score of 53/100. The AI model views Immuneering Corp as a speculative hold. While pre-revenue burn poses binary clinical risk, $128.65M in cash ($2.92/share) provides ~34 months of runway, backed by insider buying from C-suite executives. This is algorithmic model output, not personal investment advice.
Is IMRX stock a buy?
The TradeMates model verdict for IMRX is WATCH (do not buy) with an investment score of 53/100. Treat this as a model signal to review, not a personal buy recommendation.